Statin therapy increased risk for 4 of 66 adverse outcomes listed in product labels compared with placebo at a median 4.5 y

Q: What does this research mean for the field?

Statin therapy increases the risk for 4 out of 66 adverse outcomes listed in product labels compared with placebo over a median follow-up of 4.5 years. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Michael Tanner

doi:10.7326/annals-26-01782-jc

June 1, 2026Annals of Internal Medicine

Statin therapy increased risk for 4 of 66 adverse outcomes listed in product labels compared with placebo at a median 4.5 y

View at Publisher

Ask AI

Bookmark

Share

Key Points

To evaluate the risk of adverse outcomes associated with statin therapy compared to placebo.
Compared 66 adverse outcomes listed in product labels between statin therapy and placebo.
Conducted a randomized trial with a median follow-up of 4.5 years.
Statin therapy increased risk for 4 of the 66 adverse outcomes compared to placebo.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Randomized trial shows increased risk for adverse outcomes in statin treatment compared to placebo, suggesting caution in use.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Michael Tanner (2026) studied this question.

synapsesocial.com/papers/6a211549d499ed480b16e8de https://doi.org/10.7326/annals-26-01782-jc

View at Publisher

Ask AI

Bookmark

Share

Statin therapy increased risk for 4 of 66 adverse outcomes listed in product labels compared with placebo at a median 4.5 y

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Statin therapy increased risk for 4 of 66 adverse outcomes listed in product labels compared with placebo at a median 4.5 y

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading